Logo

Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis

Share this

Takeda Reports Results of Vedolizumab in its First Head-to-Head Biologic Study for Ulcerative Colitis

Shots:

  • The P-IIIb VARSITY study involves assessing of Entyvio (vedolizumab- IV) vs Humira (adalimumab- SC) in 769 patients (anti-TNFα-naïve patients & anti-TNFα-experienced patients) with moderately to severely active UC for 52wks.
  • The P-IIIb VARSITY results: @52wks. Clinical remission rates (31.3% vs 22.5%)- CRR in anti-TNFα-naïve & experienced patients (34.2% & 20.3% vs 24.3% & 16%); CRR @14wks. (26.6% vs 21.2%); Durable clinical remission (18.3% vs 11.9%); % of mucosal healing (39.7% vs 27.7%); improvement in QoL (52.0% vs 42.2%);  ≥16-point improvement in IBDQ; published in NEJM
  • Entyvio (IV) is a gut-selective mAb- designed to specifically antagonize the α4β7 integrin to intestinal (MAdCAM-1) but not (VCAM-1) and has received marketing authorization in 60+ countries including the US and EU

Click here to­ read full press release/ article |

Ref: Takeda | Image:Takeda


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions